用于实体瘤治疗的缺氧敏感型CAR-T细胞的研究进展

薛影; 毛蕴玉; 徐建青

doi:10.19401/j.cnki.1007-3639.2023.01.008

您当前的位置：

首页 >

文章列表页 >

用于实体瘤治疗的缺氧敏感型CAR-T细胞的研究进展

综述 | 更新时间：2025-12-31

- 用于实体瘤治疗的缺氧敏感型CAR-T细胞的研究进展
- Progress in construction of hypoxia-sensitive CAR-T cell for solid tumor therapy
- 中国癌症杂志 2023年33卷第1期页码：71-77
- 作者机构：
  
  1. 复旦大学生物医学研究院，上海 200030
  2. 上海市公共卫生临床中心，上海 201540
  3. 复旦大学附属中山医院生物治疗中心，上海 200030
- 作者简介：
  
  [ "薛影（ORCID: 0000-0002-4144-3583），硕士在读。" ]
  徐建青（ORCID: 0000-0003-0896-9273），博士，研究员、博士研究生导师。
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.01.008
  中图分类号： R730.5
- 收稿：2022-07-18，
  
  修回：2022-10-27，
  
  纸质出版：2023-01-30
- 稿件说明：
移动端阅览
薛影, 毛蕴玉, 徐建青. 用于实体瘤治疗的缺氧敏感型CAR-T细胞的研究进展[J]. 中国癌症杂志, 2023,33(1):71-77.

Ying XUE, Yunyu MAO, Jianqing XU. Progress in construction of hypoxia-sensitive CAR-T cell for solid tumor therapy[J]. China Oncology, 2023, 33(1): 71-77.
薛影, 毛蕴玉, 徐建青. 用于实体瘤治疗的缺氧敏感型CAR-T细胞的研究进展[J]. 中国癌症杂志, 2023,33(1):71-77. DOI： 10.19401/j.cnki.1007-3639.2023.01.008.

Ying XUE, Yunyu MAO, Jianqing XU. Progress in construction of hypoxia-sensitive CAR-T cell for solid tumor therapy[J]. China Oncology, 2023, 33(1): 71-77. DOI： 10.19401/j.cnki.1007-3639.2023.01.008.

摘要

嵌合抗原受体T（chimeric antigen receptor T，CAR-T）细胞治疗作为一种肿瘤免疫疗法已经在血液系统肿瘤的临床治疗中取得良好效果。然而，由于实体瘤缺乏肿瘤特异性抗原，大多数CAR-T细胞以同样在机体其他正常组织器官中广泛表达的肿瘤相关抗原作为识别靶点，导致脱靶效应的产生，严重时甚至会危及患者生命。由于脱靶效应的存在，CAR-T细胞治疗在实体瘤治疗领域中的应用受到严重限制。为克服CAR-T细胞治疗中脱靶效应的影响，可以利用肿瘤微环境中氧含量低的特点，设计缺氧敏感型CAR-T细胞，使其仅在乏氧的肿瘤微环境中表达靶向肿瘤相关抗原的CAR，从而避免CAR-T细胞对正常组织器官的“误伤”。本文综述缺氧敏感型CAR-T细胞构建的常用元件和思路，梳理近年来构建缺氧敏感型CAR-T细胞的研究进展，有望加强CAR-T细胞治疗的安全性，提高CAR-T细胞在实体瘤治疗中的效果。

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy

as a kind of tumor immunotherapy

has made remarkable achievements for the treatment of hematological malignancy. Disappointingly

regarding solid tumors

CAR-T cells generally target tumor-associated antigens that are also widely expressed in normal tissues because of the lack of tumor specific antigen

resulting in on-target off-tumor effects

which may even endanger patients’ lives. Measures should be taken to overcome the off-target effects which severely limit the application of CAR-T cell therapy in solid tumors. A feasible strategy is to design hypoxia-sensitive CAR-T cells

which express CAR only in the hypoxic tumor microenvironment. Therefore

the redundant “accidental injury” can be avoided. In this review

common approaches as well as recent advances in the construction of hypoxia-sensitive CAR-T cells were discussed and summarized

which has guiding significance for enhancing the safety of CAR-T cell therapy and promoting the application of CAR-T cell in solid tumors.

关键词

Keywords

references

ALLEMANI C , MATSUDA T , DI CARLO V , et al . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries [J ] . Lancet , 2018 , 391 ( 10125 ): 1023 - 1075 . DOI: 10.1016/S0140-6736(17)33326-3 http://doi.org/10.1016/S0140-6736(17)33326-3 https://linkinghub.elsevier.com/retrieve/pii/S0140673617333263 https://linkinghub.elsevier.com/retrieve/pii/S0140673617333263

SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 . DOI: 10.3322/caac.21660 http://doi.org/10.3322/caac.21660 https://onlinelibrary.wiley.com/doi/10.3322/caac.21660 https://onlinelibrary.wiley.com/doi/10.3322/caac.21660

HAN X L , BRYSON P D , ZHAO Y F , et al . Masked chimeric antigen receptor for tumor-specific activation [J ] . Mol Ther , 2017 , 25 ( 1 ): 274 - 284 . DOI: S1525-0016(16)45366-9 http://doi.org/S1525-0016(16)45366-9

赵玲娣 , 高全立 . CAR-T细胞在肿瘤治疗中的研究进展 [J ] . 中国肿瘤临床 , 2015 , 42 ( 3 ): 190 - 194 .

ZHAO L D , GAO Q L . Research progress of CAR T-cell in tumor therapy [J ] . Chin J Clin Oncol , 2015 , 42 ( 3 ): 190 - 194 .

荣斌 , 吴纯启 , 原野 , 等 . CAR-T细胞治疗产品及其非临床评价研究概述 [J ] . 中南药学 , 2019 , 17 ( 9 ): 1381 - 1385 .

RONG B , WU C Q , YUAN Y , et al . Non-clinical evaluation of CAR-T cell therapy products [J ] . Central South Pharm , 2019 , 17 ( 9 ): 1381 - 1385 .

SHKLOVSKAYA E , RIZOS H . MHC class Ⅰ deficiency in solid tumors and therapeutic strategies to overcome it [J ] . Int J Mol Sci , 2021 , 22 ( 13 ): 6741 . DOI: 10.3390/ijms22136741 http://doi.org/10.3390/ijms22136741 https://www.mdpi.com/1422-0067/22/13/6741 https://www.mdpi.com/1422-0067/22/13/6741

GARRIDO F , APTSIAURI N . Cancer immune escape: MHC expression in primary tumours versus metastases [J ] . Immunology , 2019 , 158 ( 4 ): 255 - 266 . DOI: 10.1111/imm.13114 http://doi.org/10.1111/imm.13114

常征 , 陈学武 , 王丽 , 等 . 嵌合抗原受体T细胞治疗恶性肿瘤的研究进展 [J ] . 药学研究 , 2015 , 34 ( 9 ): 534 - 536 .

CHANG Z , CHEN X W , WANG L , et al . Research progress of chimeric antigen receptor modified T cells in malignant tumor [J ] . J Pharm Res , 2015 , 34 ( 9 ): 534 - 536 .

LIM W A , JUNE C H . The principles of engineering immune cells to treat cancer [J ] . Cell , 2017 , 168 ( 4 ): 724 - 740 . DOI: S0092-8674(17)30064-8 http://doi.org/S0092-8674(17)30064-8

JUNE C H , O’CONNOR R S , KAWALEKAR O U , et al . CAR-T cell immunotherapy for human cancer [J ] . Science , 2018 , 359 ( 6382 ): 1361 - 1365 . DOI: 10.1126/science.aar6711 http://doi.org/10.1126/science.aar6711 https://www.science.org/doi/10.1126/science.aar6711 https://www.science.org/doi/10.1126/science.aar6711

ZOU F , TAN J Z , LIU T , et al . The CD39 + HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8 + T cells exhibit potent anti-HCC activity [J ] . Mol Ther , 2021 , 29 ( 5 ): 1794 - 1807 . DOI: 10.1016/j.ymthe.2021.01.021 http://doi.org/10.1016/j.ymthe.2021.01.021 https://linkinghub.elsevier.com/retrieve/pii/S1525001621000216 https://linkinghub.elsevier.com/retrieve/pii/S1525001621000216

TANG X J , ZHOU Y , LI W J , et al . T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo [J ] . J Biomed Res , 2014 , 28 ( 6 ): 468 - 475 . DOI: 10.7555/JBR.28.20140066 http://doi.org/10.7555/JBR.28.20140066

彭灿灿 , 王惠明 . CAR-T细胞治疗实体瘤的脱靶效应及优化方略 [J ] . 中国免疫学杂志 , 2021 , 37 ( 22 ): 2754 - 2758 .

PENG C C , WANG H M . Off-target effect and optimization of CAR-T cell therapy in solid tumors [J ] . Chin J Immunol , 2021 , 37 ( 22 ): 2754 - 2758 .

SCHUBERT M L , SCHMITT M , WANG L , et al . Side-effect management of chimeric antigen receptor (CAR) T-cell therapy [J ] . Ann Oncol , 2021 , 32 ( 1 ): 34 - 48 . DOI: 10.1016/j.annonc.2020.10.478 http://doi.org/10.1016/j.annonc.2020.10.478

WANG Z G , WU Z Q , LIU Y , et al . New development in CAR-T cell therapy [J ] . J Hematol Oncol , 2017 , 10 ( 1 ): 53 . DOI: 10.1186/s13045-017-0423-1 http://doi.org/10.1186/s13045-017-0423-1 http://jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0423-1 http://jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0423-1

QI C S , GONG J F , LI J , et al . Claudin18.2-specific CAR-T cells in gastrointestinal cancers: phase 1 trial interim results [J ] . Nat Med , 2022 , 28 ( 6 ): 1189 - 1198 . DOI: 10.1038/s41591-022-01800-8 http://doi.org/10.1038/s41591-022-01800-8 https://doi.org/10.1038/s41591-022-01800-8 https://doi.org/10.1038/s41591-022-01800-8

TCHOU J , ZHAO Y B , LEVINE B L , et al . Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer [J ] . Cancer Immunol Res , 2017 , 5 ( 12 ): 1152 - 1161 . DOI: 10.1158/2326-6066.CIR-17-0189 http://doi.org/10.1158/2326-6066.CIR-17-0189

XIAO Y , YU D H . Tumor microenvironment as a therapeutic target in cancer [J ] . Pharmacol Ther , 2021 , 221 : 107753 . DOI: 10.1016/j.pharmthera.2020.107753 http://doi.org/10.1016/j.pharmthera.2020.107753 https://linkinghub.elsevier.com/retrieve/pii/S0163725820302849 https://linkinghub.elsevier.com/retrieve/pii/S0163725820302849

LUO X , XU J , YU J H , et al . Shaping immune responses in the tumor microenvironment of ovarian cancer [J ] . Front Immunol , 2021 , 12 : 692360 . DOI: 10.3389/fimmu.2021.692360 http://doi.org/10.3389/fimmu.2021.692360 https://www.frontiersin.org/articles/10.3389/fimmu.2021.692360/full https://www.frontiersin.org/articles/10.3389/fimmu.2021.692360/full

SATILMIS B , SAHIN T T , CICEK E , et al . Hepatocellular carcinoma tumor microenvironment and its implications in terms of anti-tumor immunity: future perspectives for new therapeutics [J ] . J Gastrointest Canc , 2021 , 52 ( 4 ): 1198 - 1205 . DOI: 10.1007/s12029-021-00725-8 http://doi.org/10.1007/s12029-021-00725-8 https://doi.org/10.1007/s12029-021-00725-8 https://doi.org/10.1007/s12029-021-00725-8

KUMARI S , ADVANI D , SHARMA S , et al . Combinatorial therapy in tumor microenvironment: where do we stand? [J ] . Biochim Biophys Acta Rev Cancer , 2021 , 1876 ( 2 ): 188585 . DOI: 10.1016/j.bbcan.2021.188585 http://doi.org/10.1016/j.bbcan.2021.188585 https://linkinghub.elsevier.com/retrieve/pii/S0304419X21000822 https://linkinghub.elsevier.com/retrieve/pii/S0304419X21000822

PLUNDRICH D , CHIKHLADZE S , FICHTNER-FEIGL S , et al . Molecular mechanisms of tumor immunomodulation in the microenvironment of colorectal cancer [J ] . Int J Mol Sci , 2022 , 23 ( 5 ): 2782 . DOI: 10.3390/ijms23052782 http://doi.org/10.3390/ijms23052782 https://www.mdpi.com/1422-0067/23/5/2782 https://www.mdpi.com/1422-0067/23/5/2782

SIMSEK H , KLOTZSCH E . The solid tumor microenvironment-Breaking the barrier for T cells [J ] . BioEssays , 2022 , 44 ( 6 ): 2100285 . DOI: 10.1002/bies.202100285 http://doi.org/10.1002/bies.202100285 https://onlinelibrary.wiley.com/doi/10.1002/bies.202100285 https://onlinelibrary.wiley.com/doi/10.1002/bies.202100285

GOLIWAS K F , DESHANE J S , ELMETS C A , et al . Moving immune therapy forward targeting TME [J ] . Physiol Rev , 2021 , 101 ( 2 ): 417 - 425 . DOI: 10.1152/physrev.00008.2020 http://doi.org/10.1152/physrev.00008.2020 https://journals.physiology.org/doi/10.1152/physrev.00008.2020 https://journals.physiology.org/doi/10.1152/physrev.00008.2020

LI Y , ZHAO L , LI X F . Hypoxia and the tumor microenvironment [J ] . Technol Cancer Res Treat , 2021 , 20 : 15330338211036304.

SINGH S R , RAMESHWAR P , SIEGEL P . Targeting tumor microenvironment in cancer therapy [J ] . Cancer Lett , 2016 , 380 ( 1 ): 203 - 204 . DOI: 10.1016/j.canlet.2016.04.009 http://doi.org/10.1016/j.canlet.2016.04.009

BERAHOVICH R , LIU X H , ZHOU H , et al . Hypoxia selectively impairs CAR-T cells in vitro [J ] . Cancers (Basel) , 2019 , 11 ( 5 ): 602 . DOI: 10.3390/cancers11050602 http://doi.org/10.3390/cancers11050602 https://www.mdpi.com/2072-6694/11/5/602 https://www.mdpi.com/2072-6694/11/5/602

SCHILIRO C , FIRESTEIN B L . Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation [J ] . Cells , 2021 , 10 ( 5 ): 1056 . DOI: 10.3390/cells10051056 http://doi.org/10.3390/cells10051056 https://www.mdpi.com/2073-4409/10/5/1056 https://www.mdpi.com/2073-4409/10/5/1056

VAUPEL P , MULTHOFF G . Revisiting the Warburg effect: historical dogma versus current understanding [J ] . J Physiol , 2021 , 599 ( 6 ): 1745 - 1757 . DOI: 10.1113/JP278810 http://doi.org/10.1113/JP278810 https://onlinelibrary.wiley.com/doi/10.1113/JP278810 https://onlinelibrary.wiley.com/doi/10.1113/JP278810

WANG B , ZHAO Q , ZHANG Y Y , et al . Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy [J ] . J Exp Clin Cancer Res , 2021 , 40 ( 1 ): 24 . DOI: 10.1186/s13046-020-01820-7 http://doi.org/10.1186/s13046-020-01820-7 https://doi.org/10.1186/s13046-020-01820-7 https://doi.org/10.1186/s13046-020-01820-7

ALBADARI N , DENG S S , LI W . The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy [J ] . Expert Opin Drug Discov , 2019 , 14 ( 7 ): 667 - 682 . DOI: 10.1080/17460441.2019.1613370 http://doi.org/10.1080/17460441.2019.1613370 https://www.tandfonline.com/doi/full/10.1080/17460441.2019.1613370 https://www.tandfonline.com/doi/full/10.1080/17460441.2019.1613370

AL TAMEEMI W , DALE T P , AL-JUMAILY R M K , et al . Hypoxia-modified cancer cell metabolism [J ] . Front Cell Dev Biol , 2019 , 7 : 4 . DOI: 10.3389/fcell.2019.00004 http://doi.org/10.3389/fcell.2019.00004

FALLAH J , RINI B I . HIF inhibitors: status of current clinical development [J ] . Curr Oncol Rep , 2019 , 21 ( 1 ): 6 . DOI: 10.1007/s11912-019-0752-z http://doi.org/10.1007/s11912-019-0752-z

COWMAN S J , KOH M Y . Revisiting the HIF switch in the tumor and its immune microenvironment [J ] . Trends Cancer , 2022 , 8 ( 1 ): 28 - 42 . DOI: 10.1016/j.trecan.2021.10.004 http://doi.org/10.1016/j.trecan.2021.10.004 https://linkinghub.elsevier.com/retrieve/pii/S2405803321002090 https://linkinghub.elsevier.com/retrieve/pii/S2405803321002090

LEE J W , BAE S H , JEONG J W , et al . Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions [J ] . Exp Mol Med , 2004 , 36 ( 1 ): 1 - 12 . DOI: 10.1038/emm.2004.1 http://doi.org/10.1038/emm.2004.1 https://doi.org/10.1038/emm.2004.1 https://doi.org/10.1038/emm.2004.1

朱秀秀 , 王玲 , 沈俊杰 , 等 . 靶向PSCA的缺氧诱导型CAR-T的构建及体外效能研究 [J ] . 中国细胞生物学学报 , 2019 , 41 ( 4 ): 636 - 644 .

ZHU X X , WANG L , SHEN J J , et al . Construction and in vitro potency investigation of hypoxia-inducible CAR-T targeting PSCA [J ] . Chin J Cell Biol , 2019 , 41 ( 4 ): 636 - 644 .

LEE J W , KO J , JU C , et al . Hypoxia signaling in human diseases and therapeutic targets [J ] . Exp Mol Med , 2019 , 51 ( 6 ): 1 - 13 . DOI: 10.1038/s12276-019-0235-1 http://doi.org/10.1038/s12276-019-0235-1

VITO A , EL-SAYES N , MOSSMAN K . Hypoxia-driven immune escape in the tumor microenvironment [J ] . Cells , 2020 , 9 ( 4 ): 992 . DOI: 10.3390/cells9040992 http://doi.org/10.3390/cells9040992 https://www.mdpi.com/2073-4409/9/4/992 https://www.mdpi.com/2073-4409/9/4/992

KE Q D , COSTA M . Hypoxia-inducible factor-1 (HIF-1) [J ] . Mol Pharmacol , 2006 , 70 ( 5 ): 1469 - 1480 . DOI: 10.1124/mol.106.027029 http://doi.org/10.1124/mol.106.027029

CORRADO C , FONTANA S . Hypoxia and HIF signaling: one axis with divergent effects [J ] . Int J Mol Sci , 2020 , 21 ( 16 ): 5611 . DOI: 10.3390/ijms21165611 http://doi.org/10.3390/ijms21165611 https://www.mdpi.com/1422-0067/21/16/5611 https://www.mdpi.com/1422-0067/21/16/5611

JUILLERAT A , MARECHAL A , FILHOL J M , et al . An oxygen sensitive self-decision making engineered CAR T-cell [J ] . Sci Rep , 2017 , 7 : 39833 . DOI: 10.1038/srep39833 http://doi.org/10.1038/srep39833

LIAO Q B , HE H , MAO Y Y , et al . Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing [J ] . Biomark Res , 2020 , 8 ( 1 ): 56 . DOI: 10.1186/s40364-020-00238-9 http://doi.org/10.1186/s40364-020-00238-9

陈文艳 , 熊建萍 . 肿瘤缺氧及其靶向治疗研究进展 [J ] . 国际肿瘤学杂志 , 2006 , 33 ( 1 ): 8 - 11 .

CHEN W Y , XIONG J P . Research progress of tumor hypoxia and its targeted therapy [J ] . J Int Oncol , 2006 , 33 ( 1 ): 8 - 11 .

KOSTI P , OPZOOMER J W , LARIOS-MARTINEZ K I , et al . Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors [J ] . Cell Rep Med , 2021 , 2 ( 4 ): 100227 .

BRANDT L J B , BARNKOB M B , MICHAELS Y S , et al . Emerging approaches for regulation and control of CAR T cells: a mini review [J ] . Front Immunol , 2020 , 11 : 326 . DOI: 10.3389/fimmu.2020.00326 http://doi.org/10.3389/fimmu.2020.00326

LIIKANEN I , LAUHAN C , QUON S , et al . Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8 + T cells [J ] . J Clin Invest , 2021 , 131 ( 7 ): e143729 . DOI: 10.1172/JCI143729 http://doi.org/10.1172/JCI143729 https://www.jci.org/articles/view/143729 https://www.jci.org/articles/view/143729

浏览量

3063

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

MYC通过靶向CD47促进前列腺癌增殖和转移的机制研究

没食子酸增强CAR-T细胞抗实体瘤作用的研究

循环肿瘤细胞在胆管癌侵袭转移中的作用机制研究进展及展望

生物3D打印在肿瘤研究及组织工程中的应用

普列克底物蛋白2/miR-196a信号轴介导肿瘤微环境中肺癌细胞的通讯机制研究